Your browser is no longer supported. Please, upgrade your browser.
Verastem, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own1.60% Shs Outstand170.02M Perf Week5.22%
Market Cap485.91M Forward P/E- EPS next Y-0.40 Insider Trans1.85% Shs Float164.40M Perf Month16.05%
Income-67.70M PEG- EPS next Q-0.09 Inst Own50.80% Short Float3.61% Perf Quarter28.18%
Sales88.50M P/S5.49 EPS this Y77.90% Inst Trans30.07% Short Ratio2.19 Perf Half Y120.31%
Book/sh0.68 P/B4.15 EPS next Y-11.10% ROA-34.80% Target Price4.50 Perf Year-25.98%
Cash/sh0.82 P/C3.44 EPS next 5Y1.74% ROE-56.20% 52W Range1.08 - 4.67 Perf YTD32.39%
Dividend- P/FCF- EPS past 5Y22.80% ROI-38.00% 52W High-39.61% Beta0.92
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin62.80% 52W Low161.11% ATR0.14
Employees48 Current Ratio8.50 Sales Q/Q-86.10% Oper. Margin-57.60% RSI (14)62.16 Volatility4.58% 6.18%
OptionableYes Debt/Eq0.00 EPS Q/Q77.00% Profit Margin-76.50% Rel Volume0.44 Prev Close2.71
ShortableYes LT Debt/Eq0.17 EarningsMar 18 AMC Payout- Avg Volume2.71M Price2.82
Recom2.30 SMA208.96% SMA5013.29% SMA20052.53% Volume1,201,117 Change4.06%
Jun-20-19Downgrade BTIG Research Buy → Neutral
May-10-19Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18Initiated BTIG Research Buy $17
May-02-18Initiated Seaport Global Securities Buy $14
Mar-08-18Initiated B. Riley FBR, Inc. Buy $15
Sep-07-17Reiterated H.C. Wainwright Buy $6.50 → $10
Apr-13-17Initiated Oppenheimer Outperform
Mar-24-17Reiterated H.C. Wainwright Buy $5 → $6.50
Sep-29-15Downgrade Raymond James Strong Buy → Outperform
Sep-29-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15Downgrade Jefferies Buy → Hold
Sep-29-15Downgrade Cantor Fitzgerald Buy → Hold
Sep-28-15Downgrade ROTH Capital Buy → Neutral $23 → $2
Sep-28-15Downgrade Mizuho Buy → Neutral $21 → $2
Sep-09-15Initiated Raymond James Strong Buy
May-12-15Reiterated UBS Buy $30 → $24
Apr-08-15Initiated H.C. Wainwright Buy $16
Jan-23-15Reiterated ROTH Capital Buy $29 → $23
Jul-08-14Resumed Oppenheimer Perform
Feb-11-14Initiated Mizuho Buy $21
Mar-30-21 09:51AM  
Mar-25-21 10:46AM  
Mar-18-21 04:05PM  
Mar-02-21 07:00AM  
Feb-12-21 06:43AM  
Jan-20-21 08:00AM  
Jan-07-21 04:05PM  
Jan-06-21 09:13AM  
Jan-05-21 07:00AM  
Dec-29-20 08:02AM  
Dec-15-20 07:00AM  
Dec-12-20 11:18AM  
Dec-01-20 10:06AM  
Nov-30-20 07:00AM  
Nov-12-20 09:43AM  
Nov-09-20 04:05PM  
Oct-28-20 08:01PM  
Oct-14-20 10:26AM  
Oct-08-20 08:38AM  
Oct-06-20 07:00AM  
Sep-30-20 08:54AM  
Sep-18-20 11:50AM  
Sep-16-20 07:00AM  
Sep-15-20 08:51AM  
Sep-14-20 07:00AM  
Sep-10-20 04:05PM  
Aug-12-20 09:43AM  
Aug-10-20 04:59PM  
Jul-30-20 12:34PM  
Jul-06-20 07:00AM  
Jun-23-20 11:07PM  
Jun-22-20 04:05PM  
May-28-20 07:00AM  
May-19-20 09:47AM  
May-18-20 11:20AM  
May-14-20 09:31AM  
May-07-20 04:05PM  
May-04-20 03:04PM  
May-01-20 11:30AM  
Apr-27-20 12:11AM  
Apr-23-20 08:38AM  
Apr-21-20 05:18PM  
Apr-20-20 07:00AM  
Apr-15-20 09:30AM  
Apr-13-20 06:05PM  
Apr-09-20 07:30AM  
Apr-07-20 04:05PM  
Mar-30-20 10:37AM  
Mar-19-20 11:30AM  
Mar-18-20 07:01AM  
Mar-11-20 04:05PM  
Mar-10-20 09:28AM  
Feb-28-20 06:05AM  
Feb-05-20 11:52AM  
Jan-29-20 07:06AM  
Jan-21-20 11:14AM  
Jan-09-20 09:00AM  
Jan-08-20 08:12AM  
Jan-06-20 07:00AM  
Dec-17-19 07:03PM  
Dec-11-19 08:46AM  
Dec-07-19 09:00AM  
Nov-25-19 08:57AM  
Nov-15-19 11:16PM  
Nov-13-19 07:00AM  
Nov-12-19 08:12AM  
Nov-06-19 09:15AM  
Oct-30-19 07:01AM  
Oct-29-19 07:35PM  
Oct-23-19 07:00AM  
Oct-17-19 07:00AM  
Oct-09-19 11:18AM  
Oct-08-19 10:02AM  
Oct-07-19 07:00AM  
Oct-04-19 01:41PM  
Oct-03-19 02:25PM  
Sep-26-19 07:00AM  
Sep-20-19 01:00PM  
Sep-03-19 04:05PM  
Aug-06-19 08:52PM  
Aug-05-19 01:13PM  
Aug-01-19 07:25PM  
Jul-30-19 07:00AM  
Jul-29-19 04:05PM  
Jul-26-19 07:26AM  
Jul-25-19 04:05PM  
Jul-23-19 01:04PM  
Jul-03-19 07:00AM  
Jun-25-19 08:53PM  
Jun-24-19 08:33AM  
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorDec 04Buy2.1750,000108,500218,000Dec 07 11:15 AM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 25Sale1.911,161,3002,219,94116,142,051Jun 29 06:29 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 27Sale2.311,301,3003,002,09917,303,351Apr 29 04:30 PM